Bristol-Myers Squibb makes $12 million investment in Compugen, sets up research partnership

Credit: Proactive Investors- Published 6 days ago
US pharmaceutical giant Bristol-Myers Squibb (NYSE:BMY) has agreed to make a $12 million investment in Compugen Ltd (NASDAQ:CGEN), the Israeli drug developer, as part of a new partnership between the companies, which also involves shared cancer trials. The new trials will evaluate the safety and tolerability of Compugen’s...

Recent related videos from verified sources

Researchers Awarded $1 Million Prize At Magee-Womens Research Summit 00:41
Credit: KDKA CBS 2 Pittsburgh - Published 1 week ago 

Over 1 million People Without Power After Hurricane Michael 00:32
Credit: Wochit News - Published 5 days ago 

Recent related news from verified sources

Alkane Resources Ltd (ASX:ALK) has completed an investment into gold exploration company Calidus Resources Ltd (ASX:CAI) for 125 million ordinary shares at a...
15 hours ago • Proactive Investors

Saratoga Investment Corp (NYSE:SAR), the New York-based specialty finance company, fell short of Wall Street’s earnings estimate for its fiscal second quarter,...
1 week ago • Proactive Investors

The Charles Schwab Corporation (NYSE:SCHW), one of the biggest banks and brokerage groups in the US, reported standout results on Monday, mainly as a result of...
2 days ago • Proactive Investors

MMJ PhytoTech Ltd (ASX:MMJ) has an active strategy in the medicinal cannabis sector which chief executive officer Jason Conroy will outline at the Proactive CEO...
6 days ago • Proactive Investors

You might like